
|Videos|March 15, 2016
To What Extent Should People Have Access to Naloxone?
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
Advertisement
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
3
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
4
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
5














































































































































































































